Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 13/20 | 0.45 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 8/20 | 0.39 |
| ▸ | MMP9 | P14780 | 8/20 | 0.39 |
| ▸ | MMP8 | P22894 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6327650 | 0.87 | MMP13 (0.62) | MMP13MLLT1OPRM1HRH3 | |
| SCHEMBL6323539 | 0.86 | MMP13 (0.63) | MMP13MMP2MMP9 | |
| SCHEMBL6325844 | 0.86 | MMP13 (0.48) | MMP13OPRM1 | |
| SCHEMBL6331164 | 0.85 | MMP13 (0.45) | MMP13MLLT1OPRM1HRH3 | |
| SCHEMBL6326752 | 0.85 | MMP13 (0.51) | MMP13MLLT1OPRM1HRH3MMP2 | |
| SCHEMBL6326845 | 0.85 | MMP13 (0.65) | MMP13OPRM1MMP2MMP9 | |
| SCHEMBL6328283 | 0.84 | MMP13 (0.65) | MMP13MLLT1OPRM1HRH3 | |
| SCHEMBL6324191 | 0.82 | MMP13 (0.59) | MMP13MLLT1OPRM1HRH3 | |
| SCHEMBL6326016 | 0.82 | MMP13 (0.64) | MMP13MLLT1OPRM1HRH3 | |
| SCHEMBL6325865 | 0.79 | MMP13 (0.52) | MMP13MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | NOE MARK C (US) | 2005-07-21 | — | — | US | disclosed |
| US-6841671-B2 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1332146-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002034753-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | MMP13 39/4885MLLT1 2882/4885OPRM1 4335/4885 |
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 34/4885MLLT1 2984/4885OPRM1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.